相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Lack of a Clinically Significant Drug-Drug Interaction in Healthy Volunteers Between the Hepatitis C Virus Protease Inhibitor Boceprevir and the HIV Integrase Inhibitor Raltegravir
Clara T. M. M. de Kanter et al.
CLINICAL INFECTIOUS DISEASES (2013)
Quantification of human hepatocyte cytochrome P450 enzymes and transporters induced by HIV protease inhibitors using newly validated LC-MS/MS cocktail assays and RT-PCR
Li Liu et al.
BIOPHARMACEUTICS & DRUG DISPOSITION (2012)
Provisional Guidance on the Use of Hepatitis C Virus Protease Inhibitors for Treatment of Hepatitis C in HIV-Infected Persons
David L. Thomas et al.
CLINICAL INFECTIOUS DISEASES (2012)
Antiretroviral Treatment of Adult HIV Infection 2012 Recommendations of the International Antiviral Society-USA Panel
Melanie A. Thompson et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2012)
Boceprevir for Untreated Chronic HCV Genotype 1 Infection
Fred Poordad et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection
Bruce R. Bacon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Drug-drug interactions in the treatment of HIV infection: focus on pharmacokinetic enhancement through CYP3A inhibition
F. Josephson
JOURNAL OF INTERNAL MEDICINE (2010)
HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms
Ruben C. Hartkoorn et al.
PHARMACOGENETICS AND GENOMICS (2010)
Interaction of HIV protease inhibitors with OATP1B1, 1B3, and 2B1
P. Annaert et al.
XENOBIOTICA (2010)
Induction effects of ritonavir: Implications for drug interactions
Michelle M. Foisy et al.
ANNALS OF PHARMACOTHERAPY (2008)
Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction
Roger K. Verbeeck
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2008)
SCH 503034, a mechanism-based inhibitor of hepatitis C virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of alpha interferon in replicon cells
BA Malcolm et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2006)
Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients -: A randomized controlled trial
F Carrat et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2004)
Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons
RT Chung et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: A meta-analysis
CS Graham et al.
CLINICAL INFECTIOUS DISEASES (2001)
Hepatitis C virus infection - Related morbidity and mortality among patients with human immunodeficiency virus infection
HK Monga et al.
CLINICAL INFECTIOUS DISEASES (2001)
分享论文
